MaxiNovel key facts
- Developer of biotechnology focused on molecule therapeutics intended for various types of threatening cancer.
- It has raised $44.6M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Morningside Group, Lapam Capital, Beijing Zhongguancun Venture Capital Development, Suzhou Zhongxin Innovation Investment Management, Youchoose Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch MaxiNovel: the Monday email on marks, rounds and moves
MaxiNovel funding rounds
No funding rounds for MaxiNovel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
MaxiNovel investors
10 investors are on record for MaxiNovel, including Morningside Group, Lapam Capital, Beijing Zhongguancun Venture Capital Development and Suzhou Zhongxin Innovation Investment Management.
About MaxiNovel
Developer of biotechnology focused on molecule therapeutics intended for various types of threatening cancer. The company offers research-driven drug discovery development capabilities and a portfolio of targeted and immune-related therapeutic approaches focused on cancer biology, disease mechanisms,s and clinical needs, enabling healthcare systems, medical researchers, and patients to address disease burden and insufficient existing care options.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2016
- Website
- maxinovel.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
MaxiNovel doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.